fda warning letter hims & hers compounded semaglutide september 2025 and warns investors about potential liability for FDA-regulated prescription drug ads – Partnership for Safe Medicines Hims & Hers falls 8%

Competitive analysis profiles EVERSANA and CareMetx alongside Valeris and CoverMyMeds

Healthcare system shifts Reduced burden of chronic disease: Fewer cases of type 2 diabetes, cardiovascular disease, and joint disease

The name alone makes people run

As a novel inhibitor of nicotinamide N-methyltransferase (NNMT), 5-amino-1mq has shown broad application prospects in anti-aging studies

Neither Vyvanse nor Adderall is FDA-approved for weight loss, and using either drug for this purpose without a clinical diagnosis constitutes misuse of a Schedule II controlled substance

Check Your Eligibility Free Consultation (Prospective Patients) Starting July 1, 2026 , Medicare Part D covers Wegovy, Zepbound, and Foundayo for weight loss through the new GLP-1 Bridge program